Moderna Expects FY23 Product Sales Of At Least $6B Compared To Prior Range Of $6B-$8B
Portfolio Pulse from Benzinga Newsdesk
Moderna has revised its FY23 product sales forecast to at least $6B, down from the previous range of $6B-$8B. The main factor affecting sales is the U.S. vaccination rates, with the estimate based on trends from fall 2022.
November 02, 2023 | 10:37 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna's revised FY23 sales forecast could potentially impact its stock price. The lower forecast is based on U.S. vaccination rates, indicating a potential decrease in demand for its products.
Moderna's sales forecast is a key indicator of its future performance. The downward revision suggests a potential decrease in demand for its products, which could negatively impact its stock price. The U.S. vaccination rates are a significant factor in this forecast, indicating that the company's performance is closely tied to the progress of the pandemic.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100